vs
Paysign, Inc.（PAYS）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是Paysign, Inc.的1.6倍（$35.5M vs $22.8M），Paysign, Inc.净利率更高（6.0% vs -304.2%，领先310.2%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 45.8%），Paysign, Inc.自由现金流更多（$47.5M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 31.3%）
Paysign, Inc.是一家专业支付解决方案提供商，主打定制化预付卡项目、端到端支付处理服务及数字发放工具，核心服务领域覆盖医疗保健、企业激励与大众消费市场，主要业务和客户群体分布于北美地区。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
PAYS vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.6倍
$22.8M
营收增速更快
RXRX
高出635.9%
45.8%
净利率更高
PAYS
高出310.2%
-304.2%
自由现金流更多
PAYS
多$94.8M
$-47.3M
两年增速更快
RXRX
近两年复合增速
31.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $22.8M | $35.5M |
| 净利润 | $1.4M | $-108.1M |
| 毛利率 | 57.7% | 59.8% |
| 营业利润率 | 8.1% | -304.8% |
| 净利率 | 6.0% | -304.2% |
| 营收同比 | 45.8% | 681.7% |
| 净利润同比 | -0.7% | 39.6% |
| 每股收益（稀释后） | $0.02 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PAYSRXRX
| Q4 25 | $22.8M | $35.5M | ||
| Q3 25 | $21.6M | $5.2M | ||
| Q2 25 | $19.1M | $19.2M | ||
| Q1 25 | $18.6M | $14.7M | ||
| Q4 24 | $15.6M | $4.5M | ||
| Q3 24 | $15.3M | $26.1M | ||
| Q2 24 | $14.3M | $14.4M | ||
| Q1 24 | $13.2M | $13.8M |
净利润PAYSRXRX
| Q4 25 | $1.4M | $-108.1M | ||
| Q3 25 | $2.2M | $-162.3M | ||
| Q2 25 | $1.4M | $-171.9M | ||
| Q1 25 | $2.6M | $-202.5M | ||
| Q4 24 | $1.4M | $-178.9M | ||
| Q3 24 | $1.4M | $-95.8M | ||
| Q2 24 | $697.1K | $-97.5M | ||
| Q1 24 | $309.1K | $-91.4M |
毛利率PAYSRXRX
| Q4 25 | 57.7% | 59.8% | ||
| Q3 25 | 56.3% | -183.8% | ||
| Q2 25 | 61.6% | -4.9% | ||
| Q1 25 | 62.9% | -48.0% | ||
| Q4 24 | 58.9% | -181.4% | ||
| Q3 24 | 55.5% | 53.7% | ||
| Q2 24 | 52.9% | 36.2% | ||
| Q1 24 | 52.6% | 19.1% |
营业利润率PAYSRXRX
| Q4 25 | 8.1% | -304.8% | ||
| Q3 25 | 7.3% | -3327.6% | ||
| Q2 25 | 7.5% | -916.8% | ||
| Q1 25 | 13.4% | -1297.9% | ||
| Q4 24 | 3.0% | -4042.4% | ||
| Q3 24 | 4.5% | -377.1% | ||
| Q2 24 | 0.9% | -697.4% | ||
| Q1 24 | -2.0% | -698.4% |
净利率PAYSRXRX
| Q4 25 | 6.0% | -304.2% | ||
| Q3 25 | 10.3% | -3135.3% | ||
| Q2 25 | 7.3% | -894.2% | ||
| Q1 25 | 13.9% | -1373.3% | ||
| Q4 24 | 8.8% | -3935.5% | ||
| Q3 24 | 9.4% | -367.5% | ||
| Q2 24 | 4.9% | -676.6% | ||
| Q1 24 | 2.3% | -662.4% |
每股收益（稀释后）PAYSRXRX
| Q4 25 | $0.02 | $-0.17 | ||
| Q3 25 | $0.04 | $-0.36 | ||
| Q2 25 | $0.02 | $-0.41 | ||
| Q1 25 | $0.05 | $-0.50 | ||
| Q4 24 | $0.02 | $-0.56 | ||
| Q3 24 | $0.03 | $-0.34 | ||
| Q2 24 | $0.01 | $-0.40 | ||
| Q1 24 | $0.01 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $48.5M | $1.1B |
| 总资产 | $276.3M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资PAYSRXRX
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
总债务PAYSRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益PAYSRXRX
| Q4 25 | $48.5M | $1.1B | ||
| Q3 25 | $45.8M | $1.0B | ||
| Q2 25 | $42.2M | $919.1M | ||
| Q1 25 | $39.3M | $933.9M | ||
| Q4 24 | $30.4M | $1.0B | ||
| Q3 24 | $28.5M | $524.6M | ||
| Q2 24 | $26.9M | $584.4M | ||
| Q1 24 | $25.5M | $401.2M |
总资产PAYSRXRX
| Q4 25 | $276.3M | $1.5B | ||
| Q3 25 | $209.5M | $1.4B | ||
| Q2 25 | $193.9M | $1.3B | ||
| Q1 25 | $205.1M | $1.3B | ||
| Q4 24 | $179.0M | $1.4B | ||
| Q3 24 | $167.0M | $726.5M | ||
| Q2 24 | $182.3M | $775.9M | ||
| Q1 24 | $173.0M | $557.8M |
负债/权益比PAYSRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $48.1M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $47.5M | $-47.3M |
| 自由现金流率自由现金流/营收 | 208.7% | -133.1% |
| 资本支出强度资本支出/营收 | 2.6% | 3.5% |
| 现金转化率经营现金流/净利润 | 35.29× | — |
| 过去12个月自由现金流最近4个季度 | $51.2M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流PAYSRXRX
| Q4 25 | $48.1M | $-46.1M | ||
| Q3 25 | $6.8M | $-117.4M | ||
| Q2 25 | $3.6M | $-76.4M | ||
| Q1 25 | $-6.0M | $-132.0M | ||
| Q4 24 | $14.3M | $-115.4M | ||
| Q3 24 | $-20.2M | $-59.2M | ||
| Q2 24 | $20.6M | $-82.2M | ||
| Q1 24 | $8.2M | $-102.3M |
自由现金流PAYSRXRX
| Q4 25 | $47.5M | $-47.3M | ||
| Q3 25 | $6.3M | $-117.6M | ||
| Q2 25 | $3.6M | $-79.6M | ||
| Q1 25 | $-6.1M | $-133.8M | ||
| Q4 24 | $14.2M | $-116.7M | ||
| Q3 24 | $-20.3M | $-63.8M | ||
| Q2 24 | $20.4M | $-83.4M | ||
| Q1 24 | $8.2M | $-109.0M |
自由现金流率PAYSRXRX
| Q4 25 | 208.7% | -133.1% | ||
| Q3 25 | 29.2% | -2272.5% | ||
| Q2 25 | 18.6% | -413.9% | ||
| Q1 25 | -32.9% | -907.4% | ||
| Q4 24 | 91.0% | -2567.7% | ||
| Q3 24 | -133.0% | -244.6% | ||
| Q2 24 | 142.4% | -578.5% | ||
| Q1 24 | 62.1% | -789.9% |
资本支出强度PAYSRXRX
| Q4 25 | 2.6% | 3.5% | ||
| Q3 25 | 2.1% | 4.7% | ||
| Q2 25 | 0.5% | 16.4% | ||
| Q1 25 | 0.4% | 12.4% | ||
| Q4 24 | 0.7% | 28.6% | ||
| Q3 24 | 0.8% | 17.5% | ||
| Q2 24 | 1.0% | 8.2% | ||
| Q1 24 | 0.4% | 48.2% |
现金转化率PAYSRXRX
| Q4 25 | 35.29× | — | ||
| Q3 25 | 3.05× | — | ||
| Q2 25 | 2.62× | — | ||
| Q1 25 | -2.33× | — | ||
| Q4 24 | 10.43× | — | ||
| Q3 24 | -14.03× | — | ||
| Q2 24 | 29.48× | — | ||
| Q1 24 | 26.67× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PAYS
| Plasma Industry | $12.6M | 55% |
| Pharma Industry | $9.6M | 42% |
| Other | $558.4K | 2% |
RXRX
暂无分部数据
